Cullinan Therapeutics Q1 net loss widens

Cullinan Therapeutics

07/05/2026 12:08

Overview

U.S. biopharma firm's Q1 operating income loss beat analyst expectations

Net loss for Q1 widened slightly from prior year

Cash and investments totaled $393.3 mln, with runway projected into 2029

Outlook

Company expects cash resources to provide runway into 2029 under current operating plan

Result Drivers

PIPELINE ADVANCEMENT - Co cited ongoing investment in clinical-stage programs for autoimmune diseases and cancer as key driver of operating expenses

R&D SPENDING - Research and development expenses remained elevated as co advanced multiple studies

Company press release: ID:nGNX5L0WZB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$49.66 mln
Q1 Operating Income
Beat
-$53.70 mln
-$56.57 mln (10 Analysts)
Q1 Cash & Investments
$393.30 mln
Q1 Operating Expenses
$53.70 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Cullinan Therapeutics Inc is $33.00, about 120.1% above its May 6 closing price of $14.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)